For decades, parents have weighed breastfeeding against formula feeding. Now, bioengineering firm Conagen unveils a revolutionary infant formula closer to breast milk than ever before.
Breastfeeding offers proven benefits like bolstering a baby's immune system, providing optimal nutrition, and supporting early development. Yet for many mothers, challenges such as pain, physical demands, or psychological barriers make formula a practical choice.
As reported by Forbes on July 31, 2020, Boston-based Conagen, a leader in bioengineering, has developed a formula that more closely replicates breast milk. This innovation could appeal to industry giants like Nestlé, Mead Johnson, and Danone pursuing similar advancements.
Replicating breast milk is no simple task—its composition varies between mothers and even feedings. A key component is lactoferrin, the second most abundant protein in breast milk, which provides antimicrobial and antiviral protection while enhancing iron absorption.
Current formulas source lactoferrin from cow's milk, requiring costly purification that often degrades essential nutrients.
Conagen's team has bioengineered human lactoferrin using a fermentation process akin to that for cheese or wine, yielding a version nearly identical to breast milk's.
Biologists have long sought cost-effective ways to elevate formula's efficacy. Beyond lactoferrin, efforts target 200+ human milk oligosaccharides—complex sugars that nourish beneficial gut bacteria, strengthening infants' immune systems.
This advancement positions Conagen for a major role in the formula market, pending FDA approval for the new formula.
